Lawsonia intracellularis subunit vaccine

ABSTRACT

The present invention relates to nucleic acid sequences encoding novel  Lawsonia intracelluaris  proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acid sequences, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating  Lawsonia intracellulairs  infections and methods for the preparation thereof. Finally the invention relates to diagnostic tests for the detection of  Lawsonia intracellularis  DNA, the detection of  Lawsonia intracellularis  antigens and of antibodies against  Lawsonia intracellularis.

The material saved on two identical compact discs (COPY 1 and COPY 2) under the file name “Substitute Sequence Listing,” created on Feb. 24, 2006, having a size of 54 bytes is hereby incorporated by reference.

Related Applications

This application is a national phase entry under 35 U.S.C. § 371 of International Application PCT/EP2004/009995 filed Sep. 8, 2004, which claims priority to EP Application 03077861.7 filed Sep. 12, 2003, all of which are incorporated herein by reference in their entirety.

The present invention relates to nucleic acid sequences encoding novel Lawsonia intracellularis proteins, to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences, to host cells comprising such nucleic acid sequences, DNA fragments, recombinant DNA molecules and live recombinant carriers, to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines, to vaccines for combating Lawsonia intracellularis infections and methods for the preparation thereof and to diagnostic tests for the detection of Lawsonia intracellularis DNA, for the detection of Lawsonia intracellularis antigens and for the detection of antibodies against Lawsonia intracellularis.

Porcine proliferative enteropathy (PPE or PE) has become an important disease of the modern pig industry world-wide. The disease affects 15% to 50% of the growing herds and up to 30% of the individual animals in established problem herds. Today annual economical losses have been estimated US$ 5-10 in extra feed and facility time costs per affected pig. PPE is a group of chronic and acute conditions of widely differing clinical signs (death, pale and anaemic animals, watery, dark or bright red diarrhoea, depression, reduced appetite and reluctance to move, retarded growth and increased FCR). However there are two consistent features. The first, a pathological change only visible at necropsy, is a thickening of the small intestine and colon mucosa. The second is the occurrence of intracytoplasmatic small-curved bacteria in the enterocytes of the affected intestine. These bacteria have now been established as the etiological agent of PPE and have been name Lawsonia intracellularis.

Over the years Lawsonia intracellularis has been found to affect virtually all animals including monkeys, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostrich and emoe. Lawsonia intracellularis is a gram-negative, flagellated bacterium that multiplies in eukaryotic enterocytes only and no cell-free culture has been described. In order to persist and multiply in the cell Lawsonia intracellularis must penetrate dividing crypt cells. The bacterium associates with the cell membrane and quickly enters the enterocyte via an entry vacuole. This then rapidly breaks down (within 3 hours) and the bacteria flourish and multiply freely in the cytoplasm. The mechanisms by which the bacteria cause infected cells to fail to mature, continue to undergo mitosis and form hypoplastic crypt cells is not yet understood.

The current understanding of Lawsonia intracellularis infection, treatment and control of the disease has been hampered by the fact that Lawsonia intracellularis can not be cultivated in cell-free media. Although there are reports of successful co-culturing Lawsonia intracellularis in rat enterocytes this has not lead to the development of inactivated vaccines for combating Lawsonia intracellularis, although there clearly is a need for such vaccines.

It is an objective of the present invention to provide a vaccine for combating Lawsonia intracellularis infection.

It was surprisingly found now, that Lawsonia intracellularis produces six novel proteins that, alone or in combination, are capable of inducing protective immunity against Lawsonia intracellularis.

The novel proteins will be referred to as the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein.

The amino acid sequences of the novel proteins are presented in sequence identifiers SEQ ID NO: 2, 4, 6, 8, 10 and 12. The genes encoding these proteins have been sequenced and their nucleic acid sequence is shown in sequence identifiers SEQ ID NO: 1, 3, 5, 7, 9 and 11.

It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having a sequence homology of about 70% can still encode one and the same protein.

Thus, one embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, wherein those nucleic acid sequences or parts thereof have a level of homology with the nucleic acid sequence of SEQ ID NO: 1 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 95% homology with the nucleic acid sequence of SEQ ID NO: 1. Even more preferred is a homology level of 98% or even 100%.

Another approach for deciding if a certain nucleic acid sequence is or is not a nucleic acid sequence according to the invention relates to the question if that certain nucleic acid sequence does hybridise under stringent conditions to the nucleotide sequence as depicted in SEQ ID NO: 1 (or in SEQ ID NO: 3, 5, 7, 9 or 11, see below).

If a nucleic acid sequence hybridises under stringent conditions to the nucleotide sequence as depicted in SEQ ID NO: 1, or of course as depicted in SEQ ID NO: 3, 5, 7, 9 and 11, it is considered to be a nucleic acid sequence according to the invention.

The definition of stringent conditions follows from the formula of Meinkoth and Wahl (1984. Hybridization of nucleic acids immobilized on solid supports. Anal. Biochem. 138: 267-284.) Tm=[81.5° C.+16.6(log M)+0.41(% GC)−0.61(% formamide)−500/L]−1° C./1% mismatch

In this formula, M is molarity of monovalent cations; % GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs.

Stringent conditions are those conditions under which nucleic acid sequences or fragments thereof still hybridise, if they have a mismatch of 10% at the most, to the nucleic acid sequence as depicted in any of the SEQ ID NO: 1, 3, 5, 7, 9 or 11.

Also this embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, that have a level of homology with the nucleic acid sequence of SEQ ID NO: 3 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 96% homology with the nucleic acid sequence of SEQ ID NO: 3. Even more preferred is a homology level of 98% or even 100%

Also this embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, that have a level of homology with the nucleic acid sequence of SEQ ID NO: 5 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 96% homology with the nucleic acid sequence of SEQ ID NO: 5. Even more preferred is a homology level of 98% or even 100%

Also this embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, that have a level of homology with the nucleic acid sequence of SEQ ID NO: 7 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 96% homology with the nucleic acid sequence of SEQ ID NO: 7. Even more preferred is a homology level of 98% or even 100%

Also this embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, that have a level of homology with the nucleic acid sequence of SEQ ID NO: 9 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 96% homology with the nucleic acid sequence of SEQ ID NO: 9. Even more preferred is a homology level of 98% or even 100%

Also this embodiment relates to nucleic acid sequences encoding a Lawsonia intracellularis protein and to parts of that nucleic acid sequence that encode an immunogenic fragment of that protein, that have a level of homology with the nucleic acid sequence of SEQ ID NO: 11 of at least 90%.

Preferably, the nucleic acid sequence encoding this Lawsonia intracellularis protein or the part of said nucleic acid sequence has at least 92%, preferably 94%, more preferably 96% homology with the nucleic acid sequence of SEQ ID NO: 11. Even more preferred is a homology level of 98% or even 100%

Since the present invention discloses nucleic acid sequences encoding novel Lawsonia intracellularis proteins, it is now for the first time possible to obtain these proteins in sufficient quantities. This can e.g. be done by using expression systems to express the genes encoding the proteins.

Therefore, in a more preferred embodiment, the invention relates to DNA fragments comprising a nucleic acid sequence according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid sequence according to the invention is cloned. Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer, as described below.

An essential requirement for the expression of the nucleic acid sequence is an adequate promoter functionally linked to the nucleic acid sequence, so that the nucleic acid sequence is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression. Therefore, an even more preferred form of this embodiment relates to a recombinant DNA molecule comprising a DNA fragment or a nucleic acid sequence according to the invention that is placed under the control of a functionally linked promoter. This can be obtained by means of e.g. standard molecular biology techniques. (Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989. ISBN 0-87969-309-6). Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acid sequences to which they are linked.

Such a promoter can be a Lawsonia promoter e.g. the promoter involved in in vivo expression of the gene encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD or 31.4 kD gene, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the α-amylase (B. subtilis) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

When the host cell is yeast, useful expression control sequences include, e.g., α-mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G. E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P. W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R. L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985).

Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, Calif. 94303-4607, USA. Next to these expression systems, parasite-based expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in U.S. NTIS Publication No U.S. Ser. No. 08/043,109 (Hoffman, S. and Rogers, W.: Public. Date 1 Dec. 1993).

A still even more preferred form of this embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid sequence encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or an immunogenic fragment thereof according to the invention, a DNA fragment according to the invention or a recombinant DNA molecule according to the invention. Such carriers are e.g. bacteria and viruses. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid sequence encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or an immunogenic fragment thereof according to the invention has been cloned. Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein. As an example of bacterial LRCs, attenuated Salmonella strains known in the art can attractively be used.

Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid sequence into a target cell. Live recombinant carrier viruses are also called vector viruses. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S. J., Dicke, K. A., Lotzova, E. and Pluznik, D. H. (Eds.), Experimental Haematology today—1988. Springer Verlag, New York. pp. 92-99 (1989)).

The technique of in vivo homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid sequence encoding a protein according to the invention, a DNA fragment comprising such a nucleic acid sequence or a recombinant DNA molecule comprising such a nucleic acid sequence under the control of a functionally linked promoter. This form also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or a fragment thereof according to the invention.

A host cell may be a cell of bacterial origin, e.g. Escherichia coli, Bacillus subtilis and Lactobacillus species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K. A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

Another embodiment of the invention relates to the novel proteins and to immunogenic fragments thereof according to the invention.

The concept of immunogenic fragments will be defined below.

One form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of said protein.

In a preferred form, the embodiment relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

Another form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 4 and to immunogenic fragments of said protein.

A preferred form relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 4 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

Another form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 6 and to immunogenic fragments of said protein.

A preferred form relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 6 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

Another form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 8 and to immunogenic fragments of said protein.

A preferred form relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 8 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

Another form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 10 and to immunogenic fragments of said protein.

A preferred form relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 10 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

Another form of this embodiment relates i.a. to Lawsonia intracellularis proteins that have an amino acid sequence that is at least 90% homologous to the amino acid sequence as depicted in SEQ ID NO: 12 and to immunogenic fragments of said protein.

A preferred form relates to such Lawsonia intracellularis proteins that have a sequence homology of at least 92%, preferably 94%, more preferably 96% homology to the amino acid sequence as depicted in SEQ ID NO: 12 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98% or even 100%.

It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual Lawsonia intracellularis strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in “The Proteins” Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M. D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity. This explains why Lawsonia intracellularis proteins according to the invention, when isolated from different field isolates, may have homology levels of about 90%, while still representing the same protein with the same immunological characteristics.

Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with Lawsonia intracellularis or at least against the clinical manifestations of the infection are considered as “not essentially influencing the immunogenicity”.

When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An “immunogenic fragment” is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, U.S. Pat. No. 4,833,092, Proc. Natl. Acad. Sci. 81: 3998-4002 (1984), J. 1 mm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the asis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and U.S. Pat. No. 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and U.S. Patent application NTIS U.S. Ser. No. 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HUV-epitopes; The FASEB Journal 5:2412-2418 (1991).

Therefore, one form of still another embodiment of the invention relates to vaccines capable of protecting pigs against Lawsonia intracellularis infection, that comprise one or more proteins or immunogenic fragments thereof, according to the invention as described above together with a pharmaceutically acceptable carrier.

Still another embodiment of the present invention relates to the proteins according to the invention for use in a vaccine.

Still another embodiment relates to the use of a protein according to the invention for the manufacturing of a vaccine for combating Lawsonia intracellularis infections.

One way of making a vaccine according to the invention is by biochemical purification of the proteins or immunogenic fragments thereof according to the invention from bacteria obtained through mucosal scrapings taken from the infected intestine wall. This is however a very time-consuming way of making the vaccine.

It is therefore much more convenient to use the expression products of the genes encoding the proteins or immunogenic fragments thereof according to the invention in vaccines. The nucleic acid sequences of the genes encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD proteins are presented in the present invention.

Such vaccines based upon the expression products of these genes can easily be made by admixing one or more proteins according to the invention or immunogenic fragments thereof according to the invention with a pharmaceutically acceptable carrier as described below.

Alternatively, a vaccine according to the invention can comprise live recombinant carriers as described above, capable of expressing the proteins according to the invention or immunogenic fragments thereof according to the invention. Such vaccines, e.g. based upon a Salmonella carrier or a viral carrier infecting the enteric epithelium, or e.g. the respiratory epithelium have the advantage over subunit vaccines that they better mimic the natural way of infection of Lawsonia intracellularis. Moreover, their self-propagation is an advantage since only low amounts of the recombinant carrier are necessary for immunisation.

Vaccines described above all contribute to active vaccination, i.e. the host's immune system is triggered by one or more proteins according to the invention or immunogenic fragments thereof, to make antibodies against these proteins.

Alternatively, such antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the host animal. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for vaccinating immune-compromised animals. Administered antibodies against Lawsonia intracellularis can in these cases bind directly to the bacteria. This has the advantage that it immediately decreases or stops Lawsonia intracellularis growth.

Therefore, one other form of this embodiment of the invention relates to vaccines comprising antibodies against any of the six Lawsonia intracellularis proteins according to the invention.

Vaccines can also be based upon host cells as described above, that comprise the proteins or immunogenic fragments thereof according to the invention.

An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)).

This way of vaccination is very attractive for the vaccination of pigs against Lawsonia intracellularis infection.

Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acid sequences encoding a protein according to the invention or immunogenic fragments thereof according to the invention, and to vaccines comprising DNA fragments that comprise such nucleic acid sequences.

Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can easily be administered through intradermal application e.g. using a needle-less injector. This way of administration delivers the DNA-directly into the cells of the animal to be vaccinated. Amounts of DNA in the microgram range between 1 and 100 μg provide very good results.

In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from other pig pathogenic organisms and viruses, or genetic information encoding such antigens.

Such organisms and viruses are preferably selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

Methods for the preparation of a vaccine comprise the admixing of a protein according to the invention, or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.

Vaccines according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freunds Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyldipeptides, Quill A®, mineral oil e.g. Bayol® or Markol®, vegetable oil, and Carbopol® (a homopolymer), or Diluvac® Forte.

The vaccine may also comprise a so-called “vehicle”. A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle compounds are e.g. aluminium hydroxide, -phosphate or -oxide, silica, Kaolin, and Bentonite.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovamik et al; J. Bacteriology 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

In addition, the vaccine may be suspended in a physiologically acceptable diluent.

It goes without saying, that other ways of adjuvating, adding vehicle compounds or diluents, emulsifying or stabilising a polypeptide are also embodied in the present invention.

Vaccines according to the invention can very suitably be administered in amounts ranging between 1 and 100 micrograms, although smaller doses can in principle be used. A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply themselves during the infection. Therefore, very suitable amounts would range between 10³ and 10⁹ CFU/PFU for respectively bacteria and viruses.

Many ways of administration can be applied. Oral application is a very attractive way of administration, because the infection is an infection of the digestive tract. A preferred way of oral administration is the packaging of the vaccine in capsules, known and frequently used in the art, that only disintegrate after they have passed the highly acidic environment of the stomach. Also, the vaccine could be mixed with compounds known in the art for temporarily enhancing the pH of the stomach.

Systemic application is also suitable, e.g. by intramuscular application of the vaccine. If this route is followed, standard procedures known in the art for systemic application are well-suited.

From a point of view of protection against disease, a quick and correct diagnosis of Lawsonia intracellularis infection is important.

Therefore it is another objective of this invention to provide diagnostic tools suitable for the detection of Lawsonia intracellularis infection.

A diagnostic test for the detection of Lawsonia intracellularis is e.g. based upon the reaction of bacterial DNA isolated from the animal to be tested, with specific probes or PCR-primers based upon the coding sequence of the gene encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein. If Lawsonia intracellularis DNA is present in the animal, this will e.g. specifically bind to specific PCR-primers and will subsequently become amplified in PCR-reaction. The PCR-reaction product can then easily be detected in DNA gel electrophoresis.

The DNA can most easily be isolated from the micro-organisms present in swabs taken from the digestive tract of the animal to be tested. Standard PCR-textbooks give methods for determining the length of the primers for selective PCR-reactions with Lawsonia intracellularis DNA. Primers with a nucleotide sequence of at least 12 nucleotides are frequently used, but primers of more than 15, more preferably 18 nucleotides are somewhat more selective. Especially primers with a length of at least 20, preferably at least 30 nucleotides are very generally applicable. PCR-techniques are extensively described in (Dieffenbach & Dreksler; PCR primers, a laboratory manual. ISBN 0-87969-447-5 (1995)).

Nucleic acid sequences encoding a Lawsonia intracellularis protein or parts of those nucleic acid sequences having a length of at least 12, preferably 15, more preferably 18, even more preferably 20, 22, 25, 30, 35 or 40 nucleotides in that order of preference, wherein the nucleic acid sequences or parts hereof have at least 90% homology with the nucleic acid sequence as depicted in SEQ ID NO: 1 or 3. Are therefore also part of the invention. Such nucleic acid sequences can be used as primers in PCR-reactions in order to enhance the amount of DNA that they encode. This allows the quick amplification of specific nucleotide sequences for use as a diagnostic tool for e.g. the detection of Lawsonia in tissue as indicated above.

Another DNA-based test is based upon growth of bacterial material obtained from the swab, followed by classical DNA purification followed by classical hybridisation with radioactively or colour-labelled 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein-specific DNA-fragments. Both PCR-reactions and hybridisation reactions are well-known in the art and are i.a. described in Maniatis/Sambrook (Sambrook, J. et al. Molecular cloning: a laboratory manual. ISBN 0-87969-309-6).

Thus, one embodiment of the invention relates to a diagnostic test for the detection of Lawsonia intracellularis DNA. Such a test comprises a nucleic acid sequence according to the invention or a fragment thereof that is specific for the DNA encoding the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein. A fragment that is specific for that DNA is understood to be a fragment that, under comparable conditions, binds better to the Lawsonia intracellularis DNA than to DNA of other bacteria, due to higher homology with the Lawsonia intracellularis DNA, e.g. a primer of at least 12 nucleotides as described above.

A diagnostic test for the detection of Lawsonia intracellularis antibodies in sera can be e.g. a simple standard sandwich-ELISA-test in which 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or antigenic fragments thereof according to the invention are coated to the wall of the wells of an ELISA-plate. A method for the detection of such antibodies is e.g. incubation of 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or antigenic fragments thereof with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody. A colour reaction can then reveal the presence or absence of antibodies against Lawsonia intracellularis. Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or an antigenic fragment thereof according to the invention, with serum of mammals to be tested, followed by analysis of the blot.

Thus, another embodiment of the present invention relates to diagnostic tests for the detection of antibodies against Lawsonia intracellularis. Such tests comprise a protein or a fragment thereof according to the invention.

Also, the invention relates to methods for the detection in serum of antibodies against Lawsonia intracellularis, in which the method comprises the incubation of serum with the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or antigenic fragments thereof according to the invention.

A diagnostic test based upon the detection of antigenic material of the specific 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD proteins of Lawsonia intracellularis antigens and therefore suitable for the detection of Lawsonia intracellularis infection can e.g. also be a standard ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein. After incubation with the material to be tested, labelled anti-Lawsonia intracellularis antibodies are added to the wells. A colour reaction then reveals the presence of antigenic material from Lawsonia intracellularis. Therefore, still another embodiment of the present invention relates to diagnostic tests for the detection of antigenic material of Lawsonia intracellularis. Such tests comprise antibodies against a protein or a fragment thereof according to the invention.

The polypeptides or immunogenic fragments thereof according to the invention expressed as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987).

Monoclonal antibodies, reactive against the polypeptide according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by immunising inbred mice by techniques also known in the art (Kohler and Milstein, Nature, 256, 495-497, 1975).

Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described in review papers by Cortese, R. et al, (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn. 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267: 16007-16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-140 (1999) and Ghahroudi, M. A. et al., FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired antibodies can be replicated and subsequently be used for large scale expression of antibodies.

Still another embodiment of the invention relates to methods for the detection of antigenic material from Lawsonia intracellularis in which the method comprises the incubation of serum, tissue of body fluids with antibodies against the 31.0 kD, 24.8 kD, 76.7 D, 56.8 kD, 28.8 kD and 31.4 kD protein or an antigenic fragment thereof according to the invention.

Finally, an embodiment of the invention relates to nucleic acid sequences encoding a Lawsonia intracellularis protein or parts of those nucleic acid sequences having a length, wherein the nucleic acid sequences or parts hereof have at least 90% homology with the nucleic acid sequence as depicted in SEQ ID NO: 1, 3, 5, 7, 9 or 11. Such nucleic acid sequences can be used as primers in PCR-reactions in order to enhance the amount of DNA that they encode. This allows the quick amplification of specific nucleotide sequences for use as a diagnostic tool for e.g. the detection of Lawsonia in tissue as indicated above.

EXAMPLES Example 1

Isolation of L. intracellularis from Infected Porcine Ilea.

L. intracellularis infected ilea, confirmed by histopathology and acid-fast Ziehl-Neelsen staining, were collected from pigs died with PE, and stored at −80° C. After thawing L. intracellularis bacteria were isolated from mucosal scrapings taken from the infected intestinal wall. The ileal scrapings were homogenized repeatedly in PBS in an omnimixer to release the intracellular bacteria as described by Lawson et al. (Vet. Microbiol. 10: 303-323 (1985)). Supernatant obtained after low-speed centrifugation to remove cell debris was filtered through 5.0, 3.0, 1.2, and 0.8 μm filters (Millipore). The filtrate was subsequently centrifuged at 8000 g for 30 min, giving a small pellet of L. intracellularis bacteria. These bacteria were further purified using a Percoll gradient. The identity of the purified bacteria was assessed by PCR (Jones et al., J. Clin. Microbiol. 31: 2611-2615 (1993)) whereas purity of the isolated bacteria (>95%) was assessed by phase contrast microscopy to reveal any contaminating bacteria or gut debris present.

Bacterial Strains and Plasmids

E. coli host strain BL21star(DE3) containing vector pLysSrare and plasmid pET22b were purchased from Novagen (Madison, Wis., USA. pET-HIS1 (1) was constructed as described in Schaller et al., Microbiology 145: 2105-2116 (1999). E. coli strain TOP10F′ was purchased from Invitrogen (Groningen, the Netherlands). Stocks of all bacterial strains, containing 30% glycerol, were stored at −70° C.

Lawsonia intracellularis cells were isolated from infected ileal material as described above.

Culture Media, Buffers and Antibiotics

Luria Bertani broth (LB) were prepared according to standard procedures. LB plates were prepared by melting LB medium+1.5% agar in a microwave oven according to standard procedures. Plates were poured after cooling the solution down to 45° C., and if needed addition of ampicillin (ACS-Dophar, Raamsdonksveer, the Netherlands). Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from Biosynth Ag (Staad, Switzerland).

PCR Amplification

PCR amplification was performed using a Geneamp 9700 PCR system (Applied Biosystems, Calif., USA). The PCR was performed with the Expand High Fidelity PCR System (Roche Diagnostics GmbH, Mannheim, Germany). The PCR mixture contained 52 U/ml Expand High Fidelity Enzyme Mix, Expand HF buffer with 2.5 mM MgCl₂, 16 mM dNTPs (Promega, Wisconsin, USA), 20 pmoles of primers and 15 ng chromosomal DNA of Lawsonia intracellularis as template. All primers used for amplification of DNA are listed in table 1.

DNA Isolation

In order to obtain highly purified Lawsonia chromosomal DNA, DNA was prepared using a Biorad chromosomal DNA isolation kit (Biorad, Veenendaal, the Netherlands) according to manufacturers instructions.

DNA Sequencing

DNA was sequenced on an ABI 310 automated sequencer (Perkin Elmer, Calif., USA). The sequence mixture contained: 100 ng PCR product, 2 μl terminator ready reaction mix (Perkin Elmer, Calif., USA), 2.4 pmoles of primer, 6 μl of buffer (200 mM Tris-HCl, pH8.5; 5 mM MgCl₂) and aqua dest up to 20 μl. This mixture was cycled on a Geneamp 9700. The program was composed of 25 cycles with 10 seconds 96° C., 5 seconds 50° C. and 2 minutes 60° C. The cycle sequence products were purified with Dye-Ex columns (Qiagen Inc., Calif., USA) according to manufacturers instructions and run on the ABI 310 automated sequencer. Sequence results were collected using ABI 310 Collection Software version 1.0.4 (Perkin Elmer, Calif., USA) and analysed with Sequence Analysis version 3.1 (Perkin Elmer, Calif., USA). Alignments were made using Sequence Navigator version 1.0.1 (Perkin Elmer, Calif., USA). Sequence analysis was perormed using the Sequencer 4.1.4 (GeneCodes Ann Arbor, Calif., USA)

Ligation and Transformation.

Ligations were performed in a 1× ligation buffer with 1 unit of ligation enzyme (Gibco BRL Life Technologies Inc., USA) at 16° C. overnight. 1 μl of the ligation reaction was transformed to E. coli competent cells by heat shock. The BL21 star(DE3) E. coli competent cells and the TOP10F′ E. coli competent cells were made competent by a method of Maniatis/Sambrook using buffers TFB1 (30 mM KOAc, 100 mM RbCl, 10 mM CaCl₂, 50 mM MnCl₂, 15% glycerol) and TFB2 (10 mM RbCI, 75 mM CaCl₂, 10 mM MES, 15% glycerol). After 1 hour of recovery in SOC-medium supplemented with 10 mM MgSO₄ and 20 mM glucose at 37° C., the cells were plated on LB plates with the appropriate antibiotics.

Expression of 10×HIS Fusion Proteins

E. coli strain BL21star(DE3) containing pLysSrare and the expression vector was grown overnight at 37° C. at 200 rpm in 5 ml LB with ampicillin. The overnight culture was diluted 1:100 in 50 ml LB with ampicillin. This culture was grown under the same conditions until the OD₆₀₀ reached 0.5, measured on a NovaspecII spectophotometer (Pharmacia, Woerden, the Netherlands). At this point (t=0) the culture was induced with IPTG to a final concentration of 1 mM and continued to grow for a subsequent 3 hours (t=3). 100 μl samples were taken for analysis. E. coli strain BL21star(DE3) containing pLysSrare was grown and induced under the same conditions and samples were taken as a negative control. The samples were analyzed by SDS page, followed by a Coomassie Brilliant Blue staining as described below. The remaining culture was centrifuged at 5,000 rpm and the pellet was stored at −20° C. until further use.

Polyacrylamide Gel Electrophoresis and Western Blotting

SDS-PAGE was performed using 4-12% Bis-Tris gels from the NuPAGE electrophoresis system (Novex, San Diego, USA). Before separation the samples were boiled for 5 minutes with sample buffer (sample:buffer=2:1) in the presence of β-mercapto ethanol. The gels were stained with Coomassie Brilliant Blue or blotted onto Immobulon-P-membrane (Millipore, Bedford, USA) by standard semi-dry Western blotting procedures. Chicken anti-Lawsonia polyclonal serum was raised against a whole cell preparation in n-GNE (water:oil=45:55). Serum E2-839 was obtained from a pig that had developed clinical signs and post-mortem lesions typical for L. intracellularis infection. The sera were pre-adsorbed using an equal volume crude cell extracts from BL21star(DE3) containing vector pLysSrare at 4° C. for 4 hours.

TABLE 1 Primers used for the amplification and cloning of the Lawsonia intracellularis genes. PCR PCR Forward product Reverse product gene primer size primer size 11 CATGCCATGGATAGT <210> SEQ ID NO: 13 34 bp CGCGGATCCTTATTT <210> SEQ ID NO: 14 29 bp AATAATGATTCAATG <211> 34 TGGAGATGTTGACA <211> 29 ATTA <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia 3 CATGCCATGGCTAAA <210> SEQ ID NO: 15 32 bp CGCGGATCCGAAAGG <210> SEQ ID NO: 16 29 bp AAATTACTCTTTACT <211> 32 CCAGAGGGTATCCA <211> 29 TC <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia 5 CATGCCATGGCTTCG <210> SEQ ID NO: 17 32 bp CGCGGATCCCTGTTT <210> SEQ ID NO: 18 29 bp ATCAATACACTTTTC <211> 32 TAAAGAAAGTAAAG <211> 29 GG <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia 7 CATGCCATGGCTAGG <210> SEQ ID NO: 19 32 bp CGCGGATCCAATGTA <210> SEQ ID NO: 20 29 bp GTTACCCACCAATCA <211> 32 TTTTGTTAAATTTA <211> 29 AT <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia 9 CATGCCATGGCTATT <210> SEQ ID NO: 21 32 bp CGCGGATCCCGCCAG <210> SEQ ID NO: 22 29 bp TCATTAAATAATTCA <211> 32 AATACGCTGTGTTG <211> 29 TC <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia 1 CATGCCATGGCTTCT <210> SEQ ID NO: 23 32 bp CGCGGATCCGCCACT <210> SEQ ID NO: 24 29 bp TTGGTCATTAACAAC <211> 32 AATGAGTTGGCTTG <211> 29 AA <212> DNA <212> DNA <213> Lawsonia <213> Lawsonia

TABLE 2 Overview of plasmids comprising the cloned Lawsonia intracellularis genes. T7 expression cloning calculated gene vector sites molecular mass plasmid seq id 11 pET22b Ncol BamHI 30.7 kDa pET 31.4 seq id 3 pETHIS1 Ncol BamHI 26.4 kDa pET 24.8 seq id 5 pETHIS1 Ncol BamHI 78.3 kDa pET 76.7 seq id 7 pETHIS1 Ncol BamHI 58.4 kDa pET 56.8 seq id 9 pETHIS1 Ncol BamHI 28.8 kDa pET 28.8 seq d 1 pETHIS1 Ncol BamHI 32.6 kDa pET 31.0 Results Cloning of Lawsonia Genes in T7 Based Expression Vectors

Lawsonia genes were amplified by PCR using primers listed in table 1. The obtained PCR products were digested using restriction enzymes NcoI and BamHI. The digested PCR products were subsequently ligated to pET22b or pET-HIS1 that had been cut with the same two restriction enzymes as indicated in table 2. The ligation mixtures were transformed to E. coli TOP10F and incubated o/n at 37° C. Putative transformants were checked for the right plasmid using colony PCR. This resulted in 6 different expression plasmids. These plasmids were checked by nucleotide sequence analysis and sequences were as expected on basis of the cloning strategy.

Expression of Lawsonia Genes from T7 Promoter in Escherichia coli

All plasmids listed in table 2 were tested for recombinant protein production. Plasmids were transformed to BL21star(DE3)pLysSrare and an induction was performed. The induction cultures were analysed by SDS-PAGE gel electrophoresis and CBB staining (FIG. 1). All six genes gave sufficient expression in E. coli BL21star(DE3) pLysSrare. Expression levels of 150 μg/ml were reached.

Analysis of Expression Products by Western Blot

Expression products were analysed by western blot using serum of chickens vaccinated with whole Lawsonia cells and serum from a pig that displayed clinical signs and post mortem lesions that are typical for L. intracellularis (FIG. 2). The recombinant Lawsonia proteins were positively identified by the chicken and pig sera.

LEGENDS TO THE FIGURES

FIG. 1. Analysis of the over-expression of Lawsonia intracellularis genes in Escherichia coli BL21STAR/pLysSRARE by NUPAGE.

Lane 1, molecular weight marker; lane 2, pET76.7 T=0; lane 3, pET76.7 T=3; lane 4, pET56.8 T=0; lane 5, pET56.8 T=3; lane 6, pET24.8 T=0; lane 7, pET24.8 T=3; lane 8, pET28.8 T=0; lane 9, pET28.8 T=3; lane 10, pET31.0 T=0; lane 11, pET31.0 T=3; lane 12, pET31.4 T=0; lane 13, pET31.4 T=3; lane 14, T=3 no expression vector.

Arrows indicate the location of the expression products.

FIG. 2. Western blotting of expression products of Lawsonia intracellularis genes in Escherichia coli BL21STAR/pLysSRARE.

Lane 1, pET31.4; lane 2, pET28.8; lane 3, pET31.0; lane 4, pET24.8; lane 5, pET 76.7; lane 6, pET56.8; lane 7, no expression vector.

Arrows indicate the location of the expression products. 

1. An isolated and purified Lawsonia intracellularis protein, comprising the amino acid sequence of SEQ ID NO:
 2. 2. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
 3. A diagnostic test for the detection of antibodies against Lawsonia intracellularis, comprising the protein as defined in claim
 1. 